Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM57 plus rabies vaccine vs HRIG plus rabies vaccine in pediatric category III rabies exposure
CTR20201247Phase 3Completed
- Sponsor
- NCPC New Drug Research & Development
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ormutivimab in rabies, sponsored by NCPC New Drug Research & Development. Started Mar 2021; status: completed.
02
Drugs
ormutivimab
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20201247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201247.